KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives.

"We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next phase of growth," said Helena Chaye, Ph.D., CEO of KaliVir Immunotherapeutics. "Schond's appointment is a testament to our company's maturation and readiness to elevate our financial operations. His expertise will be crucial as we advance our mission to redefine cancer treatment with oncolytic virus therapy, execute our key objectives and maximize value for our stakeholders. This strategic addition to our leadership team underscores the remarkable progress we've made this year and positions us strongly for the exciting times ahead."

Prior to joining KaliVir, Mr. Greenway served as CFO at MindMed (Nasdaq: MNMD), where he was responsible for all aspects of corporate finance, investor relations, public relations and information technology. He previously served as CFO at Avalo Therapeutics (Nasdaq: AVTX). Earlier in his career, he held executive leadership roles at Mesoblast Ltd (Nasdaq: MESO), Halozyme Therapeutics (Nasdaq: HALO), and DURECT Corporation (Nasdaq: DRRX). His investment banking career began at Morgan Stanley, and he later became Vice President, Healthcare Desk Analyst at Barclays Capital. Throughout his career, Mr. Greenway has played a pivotal role in advising and participating in transactions totaling more than $30 billion. He also played a critical role in securing more than $1.5 billion in growth equity, debt capital and R&D funding from biopharmaceutical companies during his leadership tenures at MindMed, Avalo Therapeutics, and other life sciences organizations.

“Throughout my career, I have made it a priority to be a part of companies looking to advance new treatment paradigms that will make a difference in the lives of patients and I’m honored to play a role in KaliVir’s journey to transform cancer care,” said Schond Greenway, CFO of KaliVir Immunotherapeutics. “As the company's first CFO, I look forward to leveraging my experience in biotech finance to build a strong financial infrastructure that will support KaliVir's growth and innovation. I’m excited to join a team that's not only pushing the boundaries of science but also poised to create significant value for patients and shareholders alike."

About KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform, Vaccinia Enhanced Template (VET™) platform, that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and enhance intravenous delivery and spread. The VET platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients’ immune systems and modify the tumor microenvironment. The company’s lead clinical candidate VET3-TGI is now in Phase 1 development for the treatment of incurable, solid tumors. KaliVir’s oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir has announced collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET™ platform. In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir’s initial lead clinical candidate VET2-L2 oncolytic vaccinia virus. KaliVir is currently advancing multiple therapeutic candidates toward the clinic. For more information, please visit KaliVir.com.